Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma
Kuntal Halder(Translational Genomics Research Institute), Haiyong Han(Translational Genomics Research Institute), Lin Wei(Hebei Medical University), Mitsuro Kanda(Nagoya University), Susan Tsai(The Ohio State University Wexner Medical Center), Masamichi Hayashi(Nagoya University), Derek Cridebring(Translational Genomics Research Institute), Haruyoshi Tanaka(Nagoya University), Erkut Borazanci(HonorHealth), Mohammed Aldakkak(Medical College of Wisconsin), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Daniel D. Von Hoff(Translational Genomics Research Institute), Gayle Jameson(HonorHealth), Ajay Goel(City of Hope), Amber Vrana(HonorHealth)
Cited by 2
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
|Gastroenterology|2015|814
Pathways of Colorectal Carcinogenesis
|Gastroenterology|2019|594
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
|Annals of Oncology|1996|569